Potential surrogate endpoints for prostate cancer-specific survival
There have been several attempts to clearly define surrogate endpoints for prostate cancer-specific survival that could be used to shorten the length of clinical trials investigating the merits of...
View ArticleAre changes in PSA kinetics potentially indicative of metastasis-free survival?
Researchers at Johns Hopkins have provided data to support the hypothesis that, in men being treated with novel, non-hormonal agents for non-metastatic, non-castrate, biochemically recurrent prostate...
View ArticleProstate Cancer Roundtable updates national policy agenda
The Prostate Cancer Roundtable has just announced an update to its national policy agenda — to include a focus on the importance of patient-reported outcomes data affecting quality of life in trials...
View ArticleThe FDA’s “take” on pre-chemo approval of abiraterone in mCRPC
A new article in Clinical Cancer Research offers us insights into the US Food and Drug Administration’s thinking about the approval of abiraterone acetate for the treatment of chemotherapy-naive...
View ArticleEvaluation of the real utility of new biomarkers for prostate cancer risk
There is a fascinating comment by Kattan scheduled for publication in a forthcoming issue of the new journal Urology Practice. It makes a truly critical point about whether any of the new biomarkers...
View ArticleSmall problem in evaluation of NX-1207 in early stage, low-risk prostate cancer
Now here’s an embarrassing admission for a drug development company to have to make … According to a media release issued earlier today by Nymox Corp., the company is unable to accurately determine...
View ArticleCan the “bone scan index” act as a surrogate marker for survival?
One of the problems with clinical trials for late-stage prostate cancer today is that we commonly need to follow all patients until death before we can collect sufficiently accurate data to be certain...
View ArticleSo … what IS going to be “hot” at ASCO this year?
It appears that when it comes to the new data to be presented at ASCO this year, this will be the first time for several years that we don’t see some really groundbreaking new data from a large Phase...
View ArticleIs overall survival a useful endpoint for evaluating therapies for...
In a recent commentary, we looked at the utility of surrogate endpoints in evaluating therapies. In an abstract of a paper to be presented ASCO this year, Malouf et al. examined the large National...
View ArticleNadir PSA predicts survival after radiation and androgen deprivation for...
The following commentary addresses the article on risk for recurrent prostate cancer that we had mentioned briefly yesterday. If a treatment isn’t working, we want to know as quickly as possible so we...
View ArticleCTC levels as a surrogate endpoint for clinical trials in mCRPC
A newly published analysis of data from five major clinical trials involving > 6,000 patients has provided us with additional information about circulating tumor cell (CTC) levels as an endpoint for...
View ArticleMFS as an endpoint in clinical trials
Earlier this year, two drugs (apalutamide/Erleada and enzalutamide/Xtandi) were each approved for the treatment of non-metastatic, castration-resistant prostate cancer (nmCRPC) based on the use of...
View ArticleIs time to biochemical failure a good surrogate endpoint for overall survival?
For many years researchers have been trying to identify so-called “surrogate” endpoints that can be used to predict overall and prostate cancer-specific survival with high accuracy. The availability of...
View Article
More Pages to Explore .....